Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Complete remission of advanced hepatocellular carcinoma by sorafenib: A case report.

Kim MS, Jin YJ, Lee JW, Lee JI, Kim YS, Lee SY, Chae MH.

World J Gastrointest Oncol. 2013 Feb 15;5(2):38-42. doi: 10.4251/wjgo.v5.i2.38.

2.

Comparison of chemoembolization with and without radiation therapy and sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis.

Kim GA, Shim JH, Yoon SM, Jung J, Kim JH, Ryu MH, Ryoo BY, Kang YK, Lee D, Kim KM, Lim YS, Lee HC, Chung YH, Lee YS.

J Vasc Interv Radiol. 2015 Mar;26(3):320-9.e6. doi: 10.1016/j.jvir.2014.10.019. Epub 2015 Jan 19.

PMID:
25612807
3.

Sustained complete response of hepatocellular carcinoma with portal vein tumor thrombus following discontinuation of sorafenib: A case report.

Shiozawa K, Watanabe M, Ikehara T, Matsukiyo Y, Kogame M, Kanayama M, Matsui T, Kikuchi Y, Ishii K, Igarashi Y, Sumino Y.

Oncol Lett. 2014 Jan;7(1):50-52. Epub 2013 Nov 7.

4.

Complete response of advanced hepatocellular carcinoma to sorafenib : another case and a comprehensive review.

Kim TS, Kim JH, Kim BH, Lee YS, Yoo YJ, Kang SH, Suh SJ, Jung YK, Seo YS, Yim HJ, Yeon JE, Byun KS.

Clin Mol Hepatol. 2017 Jun 20. doi: 10.3350/cmh.2016.0070. [Epub ahead of print]

5.
6.

Complete response for advanced liver cancer during sorafenib therapy: case report.

Sacco R, Bargellini I, Gianluigi G, Bertini M, Bozzi E, Altomare E, Battaglia V, Romano A, Bertoni M, Capria A, Bresci G, Bartolozzi C.

BMC Gastroenterol. 2011 Jan 17;11:4. doi: 10.1186/1471-230X-11-4.

7.

Complete pathological response induced by sorafenib for advanced hepatocellular carcinoma with multiple lung metastases and venous tumor thrombosis allowing for curative resection.

Kitajima T, Hatano E, Mitsunori Y, Taura K, Fujimoto Y, Mizumoto M, Okajima H, Kaido T, Minamiguchi S, Uemoto S.

Clin J Gastroenterol. 2015 Oct;8(5):300-5. doi: 10.1007/s12328-015-0594-7. Epub 2015 Aug 7.

PMID:
26249525
8.

Deteriorated portal flow may cause liver failure in patients with hepatocellular carcinoma being treated with sorafenib.

Yamasaki A, Umeno N, Harada S, Tanaka K, Kato M, Kotoh K.

J Gastrointest Oncol. 2016 Jun;7(3):E36-40. doi: 10.21037/jgo.2015.10.07.

9.

[Combination Chemotherapy Using Sorafenib and Hepatic Arterial Infusion with a Fine-Powder Formulation of Cisplatin for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis--A Case Report].

Tsukamoto T, Kanazawa A, Shimizu S, Murata A, Sakae M, Kurihara S, Tashima T, Deguchi S, Nakai T, Kawasaki Y, Kioka K.

Gan To Kagaku Ryoho. 2015 Nov;42(12):1878-80. Japanese.

PMID:
26805203
10.
11.

Hepatocellular carcinoma presenting as an incidental isolated malignant portal vein thrombosis.

Poddar N, Avezbakiyev B, He Z, Jiang M, Gohari A, Wang JC.

J Gastrointest Cancer. 2012 Sep;43(3):486-9. doi: 10.1007/s12029-010-9235-z.

PMID:
21190093
12.

The role of sorafenib in downsizing hepatocellular carcinoma prior to liver transplantation and in treating tumor recurrence.

Sinakos E, Selvaggi G, Papalavrentios L, Tzakis A, Akriviadis E.

Ann Gastroenterol. 2011;24(3):228-230.

13.

Transcatheter arterial chemoembolization for advanced hepatocellular carcinoma with portal vein invasion: safety, efficacy, and prognostic factors.

Chern MC, Chuang VP, Liang CT, Lin ZH, Kuo TM.

J Vasc Interv Radiol. 2014 Jan;25(1):32-40. doi: 10.1016/j.jvir.2013.10.013. Epub 2013 Nov 26.

PMID:
24290099
14.

Complete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib.

Kermiche-Rahali S, Di Fiore A, Drieux F, Di Fiore F, François A, Scotté M.

World J Surg Oncol. 2013 Aug 2;11(1):171. doi: 10.1186/1477-7819-11-171.

15.

[Clinical observation of transcatheter arterial chemoembolization plus sorafenib in the treatment of advanced hepatocellular carcinoma with different types of portal vein tumor thrombosis].

Chen JW, Pang PF, Meng XC, Zhou B, Huang WS, Guo YJ, Zhu KS, Shan H.

Zhonghua Yi Xue Za Zhi. 2013 Mar 5;93(9):663-7. Chinese.

PMID:
23751743
16.

Pathological complete remission of advanced hepatocellular carcinoma with main portal vein tumor thrombosis by hepatic arterial infusion chemotherapy.

Kim YG, Eun JR, Kim TN, Lee HJ, Kim JW, Chang JC, Yun SS, Choi JH.

Gut Liver. 2010 Jun;4(2):266-9. doi: 10.5009/gnl.2010.4.2.266. Epub 2010 Jun 16.

17.

Phase 2 study of combined sorafenib and radiation therapy in patients with advanced hepatocellular carcinoma.

Chen SW, Lin LC, Kuo YC, Liang JA, Kuo CC, Chiou JF.

Int J Radiat Oncol Biol Phys. 2014 Apr 1;88(5):1041-7. doi: 10.1016/j.ijrobp.2014.01.017.

PMID:
24661657
18.

Transarterial chemoembolization with/without cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma.

Wang C, Lu Y, Wang H, Gao X, Bai W, Qu J, Xu G, Zhang Z, Zeng Z, Zhou L, An L, Lv J, Yang Y.

Exp Ther Med. 2012 Aug;4(2):188-196. Epub 2012 May 10.

19.

Late-onset benefit in progressive advanced hepatocellular carcinoma with continued sorafenib therapy: a case report.

Okuwaki Y, Nakazawa T, Hidaka H, Shibuya A, Koizumi W.

J Med Case Rep. 2012 Jan 26;6:38. doi: 10.1186/1752-1947-6-38.

20.

Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembolization combined with sorafenib--a retrospective controlled study.

Zhu K, Chen J, Lai L, Meng X, Zhou B, Huang W, Cai M, Shan H.

Radiology. 2014 Jul;272(1):284-93. doi: 10.1148/radiol.14131946. Epub 2014 Apr 6.

PMID:
24708192

Supplemental Content

Support Center